Urologists and health care professionals treating erectile dysfunction face a signi®cant challenge in caring for the HIV-positive patient who seeks restoration of normal sexual function. The encounter between the health care provider and the patient in this setting requires knowledge of HIV disease and potential drug interactions speci®c to this population, as well as thorough counseling on strategies aimed at reducing the infectiousness of HIV-1. The interaction extends beyond the immediate boundaries of the doctor ± patient relationship and their respective rights, to include careful consideration of the rights of the partneras and the society as a whole. This paper is a summary and analysis of presentations and discussions by medical, legal, nursing and bioethics specialists in an interactive seminar on this topic.
Introduction
The continuing AIDSaHIV pandemic, our aging population, and the availability of noninvasive therapies for the treatment of erectile dysfunction (ED) will probably increase the chances that we will ®nd ourselves facing an HIV-positive patient seeking to restore his potency. On the one hand, it would seem that we have a professional responsibility to treat this patient who: (a) has a`right' to health care; (b) is anxious to restore a profoundly important aspect of his well-being; and (c) might interpret any reluctance to provide him with standard impotence remedies as deliberate discrimination.
On the other hand, one must consider responsibilities to society in general and, more urgently, to the individual partneras who will be placed at risk of contracting HIV. And transmission of that incurable disease would have been made possible as the immediate result of our intervention, an act which may appear to be at odds with all the other interventions designed in the last 19 years to reduce susceptibility to HIV-1 infection.
Is there a medically and legally defensible middle ground? While there is an abundance of medical and legal writings concerning the rights of the physician and the patient, there is little that is applicable to situations where a third party (eg the partneras) may be adversely affected. 1 ± 3 This paper is a summary and review of medical, legal and ethical topics discussed at a recent CME seminar on treating erectile dysfunction in the HIV-positive male.
Medical issues and HIV in the older population
Considered a pandemic with enormous global economic and public health consequences, the number of reported cases of HIV has increased dramatically since initial reports in the summer of 1981. 4 An epidemiologic shift in incidence from the homosexual population to heterosexual couples and intravenous drug users has been noted in the United States. 4, 5 It has been estimated that 650,000 ± 900,000 people are infected with HIV in the United States, with nearly 200,000 unaware of their infection. 4 The incidence of HIV infection among the elderly increased between 1991 and 1996 and, while approximately 10% of individuals over age 50 have one or more risk factors for HIV infection, only a minority of the elderly population is tested. 6 Patients over age 50 account for approximately 10% of the reported cases of AIDS in the United States, a fact that is particularly sobering and relevant to this article, when one considers the consistent association between aging and erectile dysfunction. 7 ± 10 Counseling on safe-sex practices is critically important in the older patient population because of a variety of factors that include greater freedom to practice unprotected sex without fear of pregnancy, lack of education and information on HIV disease, and social stigma associated with HIV-positive status, leading to nondisclosure and unsafe practices. 9 The chance of HIV transmission by an HIVpositive individual is estimated to be one in 250 to one in 500 for each act of unprotected intercourse. 8 Although antiretroviral therapy has been shown to reduce the viral burden in both blood and genital secretions, the results of a large, recent study do not prove that sexual transmissions of HIV would be reduced by such treatment. 11, 12 This information must be communicated during counseling to decrease the likelihood that HIV-positive patients would engage in unsafe sex practices in the mistaken belief that their antiretoviral therapy prevents HIV transmission. 13, 14 HIV infected men may not be sexually active for a number of reasons, which include not only fear of infecting their sexual partners, but also physical dif®culty in achieving erections secondary to the effects of HIV disease. With the advent of FDA-approved oral pharmacotherapies for erectile dysfunction, some HIV infected men may be reconsidering their decision to remain celibate. Patients receiving such therapies should ideally be counseled regarding a variety of medical and social issues relevant to their HIV-positive status. These include information pertaining to safe-sex precautions, low-cost resorces available for additional counseling, HIV-related disclosure issues with casual sexual partners, and parenting issues with the possibility of infecting the female partner and subsequent prenatal tansmission to the fetus.
In addition to transmission issues, HIV-infected men and women who are considering use of medication to increase their sexual functioning need answers to questions such as: (1) How will these medications impact on the course of HIV disease? (2) How does treatment for sexual dysfunction interface with other medication that are being prescribed for HIV disease and other chronic illness such as hepatitis? (3) Is there any possibility of an adverse reaction with treatments prescribed for hypoandrogenic statesalow testosterone? (4) Does a single provider feel competent managing both HIV disease and sexual dysfunction and, if not, are the patient's two or more providers communicating? (5) Do Medicaid or private health insurers pay for the prescribed treatments?
Drug interactions
As many HIV-positive patients are expected to be taking protease inhibitors, knowledge of drug interactions between this class of drugs and medications used to treat erectile dysfunction is essential. Sildena®l and protease inhibitors are metabolized by CYP3A4. Coadministration of sildena®l with inhibitors of CYP3A4 has been shown to increase plasma sildena®l concentrations. 15 ± 17 Of the ®ve currently approved protease inhibitors for treatment of HIV-positive patients (saquinavir, indinavir, ritonavir, nel®navir and amprenavir), saquinavir is the least potent and ritonavir is the most potent inhibitor of CYP3A4. 15 Preliminary results of two randomized, placebo controlled, parallel group studies have demonstrated that when coadministered with sildena®l, both protease inhibitors increased sildena®l concentrations (Ritonavir increased sildena®l C max approximately 300%). 15 The pharmacokinetics of the protease inhibitors was unaffected by sildena®l. Other effects on sildena®l noted were increased area under the concentration vs time curve (AUC), increased time to maximum plasma concentration, and extended terminal half-life (t 1a2 ). 15 As the studies are preliminary, adverse events were not available for evaluation for the saquinavirasildena®l study. In the ritonavirasildena®l study, the most common adverse events occurring more frequently in the 14 sildena®laritonavir subjects (as compared to 14 placeboa ritonavir subjects) were visual, 7 (vs 0), ushing, 5 (vs 2), headache, 5 (vs 2), and orthostatic hypotension, 4 (vs 0). 11 The effects are most likely secondary to elevated sildena®l plasma concentrations and are consistent with the adverse event pro®le of sildena®l. 15, 16 Both drugs inhibit sildena®l ®rst-pass metabolism and ritonavir is found to have a signi®cant effect on sildena®l systemic clearance, being both a CYP3A4 and CYP2c9 inhibitor. Based on these data, as well as interaction studies in healthy volunteers, sildena®l should be used with caution (25 mg no more than once every 48 hours) in patients on ritonavir, a position supported by the European Union's Committee for Proprietary Medicinal Products. 17 Concomitant use of sildena®l with other protease inhibitors is expected to increase sildena®l levels based on similar pharmacodynamics. In patients receiving sildena®l in conjunction with saquinavir, a starting sildena®l dose of 25 mg should be considered. 15, 16 Others have suggested that for patients on indinavir, the starting dose of sildena®l should be 12.5 mg and adminis-tered no more than twice per week. 17 As in the non-HIV-positive patients, coadministration of sildena®l with organic nitrates, including amyl nitrate or poppers', is absolutely contraindicated and may result in a profound and serious, possibly fatal, hypotensive episode. 18 
Ethical considerations
A blanket refusal to treat any and all HIV positive males for erectile dysfunction would seem dif®cult to justify on any ethical grounds. Readily treating all such patients (except those excluded for technical, medical reasons) also seems morally lazy. As with most clinical issues, the most intellectually interesting and practically useful questions arise in response to an assumption that responsible practitioners would wish to reserve the option of declining to treat at least some HIV positive men for whom treatment is not otherwise contraindicated on an explicitly medical basis.
In addition to what an appropriately trained attorney might advise, physicians and other health professionals should seek guidance from such ethical sources as professional codes, authoritative position statements, established ethical principles and thoughtful analyses published in the professional literature. In this particular area, there appears to be very little moral guidance available from any of these sources.
We can start by acknowledging that we are professionals who, to the extent we are able, both want to and are obliged to assist those in need of our services. In ethics, this is usually called the Principle of Bene®cence (literally,`good doing'). 19 Much of the time, it is rather easy to discern what it means to behave bene®cently. However,`good doing' is sometimes elusive. For example, it is often not clear how to proceed medically when a patient is elderly and burdened with a number of chronic diseases or when a patient is immunocompromised or when a patient is non-compliant because of psychiatric disabilities. Bene®taharm analyses, relatively straightforward in most situations, can become major challenges in these cases.
Considering the HIV-positive patient seeking treatment for erectile dysfunction, it seems reasonable to assume that effective treatment would be lifeenhancing and therefore bene®cial. Admittedly, persons with low CD-4 counts are well advised to sharply limit intimate physical exposures of any kind, and there are data suggesting that the same may be true for other immunocompromised conditions, whether or not their CD-4 counts happen to be low. However, these latter considerations are value choices to be made with the patient, not by the physician alone.
This brings us to the Principle of Autonomy, by which is meant the obligation to respect the personhood of one's patient. 19 The ethical and legal obligation to obtain informed consent is a prime example. Respect for persons may seem to suggest that, if a decisionally intact patient of adult years asks for Viagra (sildena®l cirate), a physician will give it to him unless there is some very clear medical contraindication. However, there are other principles and they must all be brought into the equation before one can properly draw conclusions.
The Principle of Justice refers to our obligation to be fair or to`give each his due'. 19 Our notions of what is fair to others may lead us to recognize limits on the autonomy of ourselves or another. The famous line about none of us having the right to yell`Fire!' in a crowded theater ®ts here. Finally, we have come to an ethical warrant for the physician who may want to decline to treat erectile dysfunction in at least some HIV positive patients. The most common concern of conscientious physicians about treating erectile dysfunction in HIV-positive patients is that restored function in such patients may markedly increase the chances of HIV spreading to previously uninfected persons. Everyone acknowledges hearing reports, if not personal experiences, involving men who knowingly infected many others, whether through sociopathic vindictiveness, lack of self-discipline, or extreme denial. Conscientious health professionals may regard with horror the thought of being implicated in such a scenario. They would prefer to refuse to treat a man if they had substantial information that he would not use his restored capabilities in a responsible manner.
Again, the ethical grounding for such professional behavior could be rooted in the Principle of Justice. The argument might go like this: our obligations to do good for our patients (Bene®cence) and to treat them as they would have us treat them (Autonomy) is constrained by, among other things, our obligation to not disadvantage others unfairly (Justice). To knowingly put another person in harm's way (without special justi®cation) is unjust. Restoring potency to an HIV-positive man who is likely to infect others would be to put other persons at signi®cant and avoidable risk. Therefore, if possible one should decline to restore potency to a man who one believes is likely to infect others on grounds that to do so would violate the Principle of Justice.
What objections could be brought against this line of reasoning? One could object that it is not the physician who commits an injustice, but the patient. This is analogous to the complaint that`Guns don't kill people; people kill people'. However, the truth of that statement does not obviate arguments in favor of reasonable measures to assure the guns are not routinely made available to criminals, mentally deranged persons or children. The premise here is that avoidance of an injustice has priority over the wish to provide a bene®t or do as one's patient asks. In other words, Justice ordinarily trumps Bene®-cence and Autonomy. One might also make a similar argument by way of an appeal to the Principle of Non-male®cence, classically expressed as`First, do no harm'. In this version, one can again count on the traditional notion that negative obligations have priority over positive obligations, ie that one should not do bad things for good reasons or good things that entail foreseeable and signi®cant harm.
Legal issues
The American with Disabilities Act (ADA), 42 USC section 12182 (a) provides:
No individual shall be discriminated against on the basis of disability in the full and equal enjoyment of the goods, services, facilities, privileges, advantages, or accommodations of any place of public accommodation by any person who owns, leases (or leases to), or operates a place of public accommodation.
A place of public accommodation speci®cally includes a professional of®ce of a health care provider and hospital. 20 In Bragdon v Abbott, the United States Supreme Court held that the person diagnosed as being HIV-positive is entitled to the protections of the ADA whether or not they are symptomatic. 21 Consequently, a person who enters a doctor's of®ce for medical care, and is HIV-positive, cannot generally be denied medical care on that basis.
This was the ®rst AIDS case considered by the Supreme Court and indicated that the protection offered in this speci®c case may be applicable to all people with HIV infection. 21 ± 23 The court was satis®ed that the evidence was suf®cient to show asymptomatic HIV infection as a physical impairment with`immediate, constant, and detrimental physical effects F F F that`substantially limits' the major life activity of reproduction'. 2 A physician may refuse to treat a person with HIVaAIDS under the ADA if the treatment of that condition`poses a direct threat to the health or safety of others'. 24 A direct threat is a`signi®cant risk to the health or safety of others that cannot be eliminated by a modi®cation of policies, practices, or procedures, or by the provision of auxiliary aids or services'. 42 USC, section 12182 (b) (3) .`The existence, or nonexistence, of a signi®cant risk must be determined from the standpoint of the person who refuses the treatment or accommodation, and the risk assessment must be based on medical or other objective evidence.' 21 Further,`when determining whether an individual poses a`direct threat', a place of public accommodation must not base its calculus on stereotypes or generalizations about the effects of disability, but rather must make an individual assessment, based on a reasonable judgment that relies on current medical knowledge or on the best available objective evidence'. 21, 25 The person who refuses to treat or accommodate must prove that the risk is signi®cant and individually assess mode of transmission, severity of harm, probability of transmission, and duration of infectiousness. 2, 26, 27 Moreover, generalizations, irrational fears, and stereotypes should not have any role in the process of risk assessment. 28, 29 Without objective evidence and scienti®c data, the health care provider's good faith belief that signi®cant risk may exist does not excuse discrimination. 2 There are no legal maxims that are applicable to every set of facts. This is especially true when dealing with the law governing the physician ± patient relationship in the context of AIDS and HIVpositive status. Based on the Supreme Court's ruling in Bragdon, the majority of HIV-positive persons in the United States live in areas where asymptomatic infection may be inferred to be a`disability' with protections rooted in federal as well as state and local laws. 2 There is currently no medical standard of care that would hold a practitioner responsible for knowing that the HIV-positive patient with erectile dysfunction may act recklessly in the future after regaining potency. Accordingly, there are very rare instances when refusal to treat will be legally justi®able.
Maintaining consistent, meticulous and thorough documentation of patient encounters combined with informed consent should help protect health care professionals from liability against third party lawsuits. The informed consent should be in writing and have the patient acknowledge that he received informed consent by signing the document that provides it. If the patient is involved with a partner and is willing to include himaher in counseling, ideally the partner should be present for the initial counseling session and sign an informed consent acknowledgment.
Conclusions
It is only reasonable to predict that the combination of our aging population and the growing HIV pandemic will continue to raise the number of HIV-positive men seeking treatment for erectile dysfunction. The conscientious health professional is still left with substantial and dif®cult questions. Can one really be sure that one's patient will utilize his newly erectile penis responsibly? How can one be sure of that? What counts as`Sure enough'? What is ethically justi®able behavior by a physician who is still not sure, despite what heashe thinks are reasonable attempts to discern the patient's reliability? Although many more questions are raised than answered, this project was not aimed at discovering`The Right Answer', but rather at examining objectively a dif®cult, real-time, clinical dilemma for which there has been little written or discussed to-date. More work is needed before universal guidelines can be proposed to help resolve these
